Christoph Kahl

4PUBLICATIONS
28CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Innate immunityAgricultural molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Nov 18, 2025
Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer.

Arndt Stahler, Dominik Paul Modest, Sebastian Stintzing

|Jun 23, 2023
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study.

Sebastian Stintzing, Kathrin Heinrich, David Tougeron

|Jul 19, 2019
Enhancing safety of cytomegalovirus-based vaccine vectors by engaging host intrinsic immunity.

Emily E Marshall, Daniel Malouli, Scott G Hansen

|Apr 06, 2018
Ultrafiltered recombinant AAV8 vector can be safely administered in vivo and efficiently transduces liver.

Mark D Kleven, Michelle M Gomes, Aaron M Wortham

Pageof 1